RU2007108290A - Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с - Google Patents
Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с Download PDFInfo
- Publication number
- RU2007108290A RU2007108290A RU2007108290/13A RU2007108290A RU2007108290A RU 2007108290 A RU2007108290 A RU 2007108290A RU 2007108290/13 A RU2007108290/13 A RU 2007108290/13A RU 2007108290 A RU2007108290 A RU 2007108290A RU 2007108290 A RU2007108290 A RU 2007108290A
- Authority
- RU
- Russia
- Prior art keywords
- virus
- pharmaceutical composition
- hcv
- inducing
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (8)
1. Рекомбинантный вирус оспы домашней птицы, содержащий ДНК-фрагмент, происходящий от вируса гепатита С (HCV), где указанный ДНК-фрагмент кодирует фрагмент полипротеина сердцевины-Е1, состоящего из аминокислотной (а.к.) последовательности, представленной в SEQ ID NO:1 и соответствующей аминокислотам 79-338 указанного полипептида.
2. Рекомбинантный вирус оспы домашней птицы, содержащий ДНК-фрагмент, происходящий от HCV, где указанный ДНК-фрагмент кодирует химерный белок, состоящий из аминокислотной последовательности, представленной в SEQ ID NO:2, где указанный химерный белок содержит эпитопы HCV, специфичные к хелперным и цитотоксическим Т-клеткам.
3. Вирус оспы домашней птицы по п.1 или 2, происходящий от pFP67xgpt.
4. Фармацевтическая композиция для индуцирования специфического клеточного иммунного ответа против HCV, содержащая эффективное иммунизующее количество рекомбинантного вируса оспы домашней птицы по пп.1-3, и фармацевтически приемлемый наполнитель.
5. Фармацевтическая композиция по п.4, где указанная эффективная для иммунизации доза составляет от 2,5·107 до 1·108 б.о.е/дозу.
6. Фармацевтическая композиция по пп.4 и 5, индуцирующая профилактический иммунный ответ против HCV-инфекции.
7. Фармацевтическая композиция по пп.4 и 5, индуцирующая иммунный ответ против HCV у пациентов с хроническим гепатитом С, циррозом и раком печени.
8. Фармацевтическая композиция по пп.4 и 5, индуцирующая иммунный ответ против HCV до проведения другой терапии или вакцинации, либо одновременно с ее проведением, либо после ее проведения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CUCU2004-0174 | 2004-08-11 | ||
CU20040174A CU23470A1 (es) | 2004-08-11 | 2004-08-11 | Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2007108290A true RU2007108290A (ru) | 2008-09-20 |
RU2353651C2 RU2353651C2 (ru) | 2009-04-27 |
Family
ID=40262893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007108290/13A RU2353651C2 (ru) | 2004-08-11 | 2005-08-10 | Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1787656A1 (ru) |
JP (1) | JP2008508890A (ru) |
KR (1) | KR20070040814A (ru) |
CN (1) | CN101035560A (ru) |
AR (1) | AR050451A1 (ru) |
AU (1) | AU2005270612A1 (ru) |
BR (1) | BRPI0514274A (ru) |
CA (1) | CA2575293A1 (ru) |
CU (1) | CU23470A1 (ru) |
MX (1) | MX2007001749A (ru) |
MY (1) | MY170516A (ru) |
RU (1) | RU2353651C2 (ru) |
WO (1) | WO2006015557A1 (ru) |
ZA (1) | ZA200701079B (ru) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
ATE290592T1 (de) * | 1993-11-04 | 2005-03-15 | Innogenetics Nv | Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis |
CU22642A1 (es) | 1996-12-12 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso |
AU6226100A (en) * | 1999-07-19 | 2001-04-24 | Epimmune, Inc. | Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
WO2002080648A2 (en) * | 2001-04-05 | 2002-10-17 | Chiron Corporation | Mucosal boosting following parenteral priming |
-
2004
- 2004-08-11 CU CU20040174A patent/CU23470A1/es unknown
-
2005
- 2005-08-09 MY MYPI20053696A patent/MY170516A/en unknown
- 2005-08-09 AR ARP050103317A patent/AR050451A1/es unknown
- 2005-08-10 RU RU2007108290/13A patent/RU2353651C2/ru not_active IP Right Cessation
- 2005-08-10 CN CNA2005800342987A patent/CN101035560A/zh active Pending
- 2005-08-10 JP JP2007525153A patent/JP2008508890A/ja active Pending
- 2005-08-10 MX MX2007001749A patent/MX2007001749A/es unknown
- 2005-08-10 CA CA002575293A patent/CA2575293A1/en not_active Abandoned
- 2005-08-10 BR BRPI0514274-1A patent/BRPI0514274A/pt not_active IP Right Cessation
- 2005-08-10 WO PCT/CU2005/000004 patent/WO2006015557A1/es active Application Filing
- 2005-08-10 KR KR1020077003636A patent/KR20070040814A/ko not_active Application Discontinuation
- 2005-08-10 AU AU2005270612A patent/AU2005270612A1/en not_active Abandoned
- 2005-08-10 EP EP05773842A patent/EP1787656A1/en not_active Withdrawn
-
2007
- 2007-02-06 ZA ZA200701079A patent/ZA200701079B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MY170516A (en) | 2019-08-08 |
JP2008508890A (ja) | 2008-03-27 |
CU23470A1 (es) | 2009-12-17 |
EP1787656A1 (en) | 2007-05-23 |
BRPI0514274A (pt) | 2008-06-10 |
MX2007001749A (es) | 2007-04-20 |
WO2006015557A1 (es) | 2006-02-16 |
KR20070040814A (ko) | 2007-04-17 |
CA2575293A1 (en) | 2006-02-16 |
CN101035560A (zh) | 2007-09-12 |
AR050451A1 (es) | 2006-10-25 |
AU2005270612A1 (en) | 2006-02-16 |
RU2353651C2 (ru) | 2009-04-27 |
ZA200701079B (en) | 2008-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tokushige et al. | Expression and immune response to hepatitis C virus core DNA–based vaccine constructs | |
JP2017515508A5 (ru) | ||
RU2005113692A (ru) | Вакцина против hcv | |
RU2004116914A (ru) | Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения | |
AU2013339846B2 (en) | Chimeric vaccine antigens against hepatitis C virus | |
CN101717433A (zh) | 一种多肽免疫原及其制备方法和应用 | |
KR101723900B1 (ko) | 면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형 | |
RU2007108290A (ru) | Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с | |
KR100628411B1 (ko) | C형 간염 바이러스의 비구조 단백질을 이용한 유전자면역법 | |
US10160979B2 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis C | |
ES2299626T3 (es) | Aumento de timosina para asegurar una inmunizacion genetica. | |
US7078500B1 (en) | Genetic immunization with nonstructural proteins of hepatitis C virus | |
RU2362586C2 (ru) | Фармацевтические композиции для терапевтического применения | |
JPH06199894A (ja) | C型肝炎ウイルスのコア蛋白質領域に存在するt細胞エピトープ | |
AU2002360315B2 (en) | Thymosin augmentation of genetic immunization | |
JP2008508890A6 (ja) | 組換え生鶏痘ウィルスベクター及びc型肝炎ウィルスに対する薬剤組成物中でのそれらの使用 | |
AU2002360315A1 (en) | Thymosin augmentation of genetic immunization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100811 |